NCT07130331View on ClinicalTrials.gov

Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

July 1, 2024

Study Completion Date

August 1, 2025

Conditions
Axial Spondylarthritis (axSpA)Secukinumab
Interventions
DRUG

Secikinumab

secukinumab 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg s.c. every 4 weeks

Trial Locations (1)

210008

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT07130331 - Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis | Biotech Hunter | Biotech Hunter